Neurology
Competitive landscape report · 67 products · 21 companies
Executive Summary
The neurology landscape features 67 products in active development across 21 companies. The space remains highly competitive with significant activity across all clinical stages.
16 products are currently in Phase 3 trials, 31 in Phase 2, and 12 in Phase 1. Leading companies by pipeline count include Eli Lilly, Cassava Sciences, Alector.
1 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.
Top Products by Hype Score
Top Companies by Pipeline Count
Phase Distribution
Key Trends & Analysis
ProMarket consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.
Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.
Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.
Upgrade to Pro for full analysis
View plans